A good night's sleep begins with healthy gut bacteria. Here's how to look after yours

It's no accident that we spend a third of our lives asleep. It is essential to our health, and even animals for whom resting ...
Tech Times

Masters of the Universe 2026: Eternia’s Power Lives in Synaptic States, Not the Sword

Masters of the Universe 2026 opened to a franchise-best 88% audience score, and its four Eternia mechanisms each have a ...
New Zealand Science Media Centre

What’s the hype with peptides and are they safe? – Expert Q&A

A poorly regulated grey market is growing online around unapproved peptides, which are being promoted on social media for ...

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis ...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to ...
The Manila Times

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis ...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...
The Manila Times

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction…

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat ...

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while ...

Company announcement No. 21 / 2026Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and ...

Boehringer Ingelheim Limited: Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in ...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...